247 related articles for article (PubMed ID: 36230787)
1. Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma?
Krossa I; Strub T; Aplin AE; Ballotti R; Bertolotto C
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230787
[TBL] [Abstract][Full Text] [Related]
2. Role for the nuclear receptor-binding SET domain protein 1 (NSD1) methyltransferase in coordinating lysine 36 methylation at histone 3 with RNA polymerase II function.
Lucio-Eterovic AK; Singh MM; Gardner JE; Veerappan CS; Rice JC; Carpenter PB
Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16952-7. PubMed ID: 20837538
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma.
Berdasco M; Ropero S; Setien F; Fraga MF; Lapunzina P; Losson R; Alaminos M; Cheung NK; Rahman N; Esteller M
Proc Natl Acad Sci U S A; 2009 Dec; 106(51):21830-5. PubMed ID: 20018718
[TBL] [Abstract][Full Text] [Related]
4. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
Morishita M; Mevius D; di Luccio E
BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
[TBL] [Abstract][Full Text] [Related]
5. Cancers and the NSD family of histone lysine methyltransferases.
Morishita M; di Luccio E
Biochim Biophys Acta; 2011 Dec; 1816(2):158-63. PubMed ID: 21664949
[TBL] [Abstract][Full Text] [Related]
6. Identification of alternative transcripts of NSD1 gene in Sotos Syndrome patients and healthy subjects.
Conteduca G; Testa B; Baldo C; Arado A; Malacarne M; Candiano G; Garbarino A; Coviello DA; Cantoni C
Gene; 2023 Jan; 851():146970. PubMed ID: 36261088
[TBL] [Abstract][Full Text] [Related]
7. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.
Topchu I; Pangeni RP; Bychkov I; Miller SA; Izumchenko E; Yu J; Golemis E; Karanicolas J; Boumber Y
Cell Mol Life Sci; 2022 May; 79(6):285. PubMed ID: 35532818
[TBL] [Abstract][Full Text] [Related]
8. Steric Clash in the SET Domain of Histone Methyltransferase NSD1 as a Cause of Sotos Syndrome and Its Genetic Heterogeneity in a Brazilian Cohort.
Ha K; Anand P; Lee JA; Jones JR; Kim CA; Bertola DR; Labonne JD; Layman LC; Wenzel W; Kim HG
Genes (Basel); 2016 Nov; 7(11):. PubMed ID: 27834868
[TBL] [Abstract][Full Text] [Related]
9. The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.
Bennett RL; Swaroop A; Troche C; Licht JD
Cold Spring Harb Perspect Med; 2017 Jun; 7(6):. PubMed ID: 28193767
[TBL] [Abstract][Full Text] [Related]
10. Structural insights into the regulation and the recognition of histone marks by the SET domain of NSD1.
Morishita M; di Luccio E
Biochem Biophys Res Commun; 2011 Aug; 412(2):214-9. PubMed ID: 21806967
[TBL] [Abstract][Full Text] [Related]
11. NSD1 PHD domains bind methylated H3K4 and H3K9 using interactions disrupted by point mutations in human sotos syndrome.
Pasillas MP; Shah M; Kamps MP
Hum Mutat; 2011 Mar; 32(3):292-8. PubMed ID: 21972110
[TBL] [Abstract][Full Text] [Related]
12. Histone methylation mediated by NSD1 is required for the establishment and maintenance of neuronal identities.
Zheng Y; Zhao C; Song Q; Xu L; Zhang B; Hu G; Kong X; Li S; Li X; Shen Y; Zhuang L; Wu M; Liu Y; Zhou Y
Cell Rep; 2023 Dec; 42(12):113496. PubMed ID: 37995181
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation analysis of multiple imprinted DMRs in Sotos syndrome reveals IGF2-DMR0 as a DNA methylation-dependent, P0 promoter-specific enhancer.
Watanabe H; Higashimoto K; Miyake N; Morita S; Horii T; Kimura M; Suzuki T; Maeda T; Hidaka H; Aoki S; Yatsuki H; Okamoto N; Uemura T; Hatada I; Matsumoto N; Soejima H
FASEB J; 2020 Jan; 34(1):960-973. PubMed ID: 31914674
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
15. NMR backbone resonance assignment and solution secondary structure determination of human NSD1 and NSD2.
Amin N; Nietlispach D; Qamar S; Coyle J; Chiarparin E; Williams G
Biomol NMR Assign; 2016 Oct; 10(2):315-20. PubMed ID: 27356987
[TBL] [Abstract][Full Text] [Related]
16. The H3.3 G34W oncohistone mutation increases K36 methylation by the protein lysine methyltransferase NSD1.
Bröhm A; Schoch T; Grünberger D; Khella MS; Schuhmacher MK; Weirich S; Jeltsch A
Biochimie; 2022 Jul; 198():86-91. PubMed ID: 35341929
[TBL] [Abstract][Full Text] [Related]
17. NSD1: A Lysine Methyltransferase between Developmental Disorders and Cancer.
Tauchmann S; Schwaller J
Life (Basel); 2021 Aug; 11(9):. PubMed ID: 34575025
[TBL] [Abstract][Full Text] [Related]
18. The NSD family of protein methyltransferases in human cancer.
Vougiouklakis T; Hamamoto R; Nakamura Y; Saloura V
Epigenomics; 2015 Aug; 7(5):863-74. PubMed ID: 25942451
[TBL] [Abstract][Full Text] [Related]
19. Role of NSD1 as potential therapeutic target in tumor.
Yang C; Wang K; Liang Q; Tian TT; Zhong Z
Pharmacol Res; 2021 Nov; 173():105888. PubMed ID: 34536546
[TBL] [Abstract][Full Text] [Related]
20. Substrate specificity analysis and novel substrates of the protein lysine methyltransferase NSD1.
Kudithipudi S; Lungu C; Rathert P; Happel N; Jeltsch A
Chem Biol; 2014 Feb; 21(2):226-37. PubMed ID: 24412544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
